Please assess the completion status of the following clinical trial:

Trial Title: A Follow-up Trial of Proglucamune® in the Treatment of Protective Qi Deficiency, a TCM Condition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or females aged 18 to 65 years (inclusive) without regard to race or ethnic background~2. Provide a signed Informed Consent prior to entry in the study.~3. Willing to follow all study instructions and consume the assigned investigational product for 12 weeks.~4. Not currently taking a beta-glucan containing supplement or any other supplement that might interfere with the study design.~5. Ability to swallow tablets and pills.~6. Exhibit an PQi Insufficiency score \> 2 (See Primary Outcome Measure)~Exclusion Criteria:~1. Persons diagnosed by TCM as having medical conditions other than low Qi.~2. Significant acute or chronic illness or other medical conditions that will prevent or interfere with giving an informed consent, or with participation in the study.~3. Scheduling difficulties or lack of transportation that will prevent or interfere with their ability to attend all of the necessary study visits.~4. Persons medically diagnosed with depression or anxiety disorders.~5. Persons with a history of alcohol abuse or other substance abuse within the previous 2 years.~6. Females who are attempting to become pregnant, pregnant, lactating or who have given birth within 1 year.~7. Persons who have had a medical surgery in the past 4 weeks or have scheduled a surgery during the study period.~8. Persons currently enrolled in a clinical trial, or who have completed a clinical trial within the last 4 weeks.~9. Allergies to mushrooms or other fungi.~10. Significant problems with constipation or diarrhea.~11. A lifestyle or schedule incompatible with the study protocol.~12. Persons who are allergic to yeast products, have autoimmune disease/an immune disorder, or take antidepressants, blood thinners (anticoagulants, acetylsalicylic acid), or immunosuppressant medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Proglucamune treatment (Type: EXPERIMENTAL): Participants were treated with 2 tablets of Proglucamune per day (containing 200mg of beta glucan) for a total duration of 8 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants were treated with 2 tablets of placebo per day (contain no beta glucan) for a total duration of 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).